플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study.

Authors

Jespersen L, Tarnow I, Eskesen D, Morberg CM, Michelsen B, Bügel S, Dragsted LO, Rijkers GT, Calder PC.

Journal

Am J Clin Nutr.

Year

2015

Vol (Issue)

101(6)

Page

1188-96.

doi

10.3945/ajcn.114.103531.

PMID

25926507

Url

http://www.ncbi.nlm.nih.gov/pubmed/25926507

MeSH

Adolescent
Adult
Animals
Antibodies, Viral/blood
Body Mass Index
Colony Count, Microbial
Denmark
Double-Blind Method
Female
Germany
Healthy Volunteers
Hemagglutination Inhibition Tests
Humans
Influenza Vaccines/therapeutic use
Influenza, Human/immunology*
Influenza, Human/prevention & control
Lactobacillus casei*
Male
Middle Aged
Milk
Probiotics/administration & dosage*
Respiratory Tract Infections/immunology
Respiratory Tract Infections/prevention & control*
Treatment Outcome
Vaccination*
Young Adult

Keywords

immune function; probiotics; upper respiratory tract infection; Lactobacillus paracasei subsp. Paracasei; vaccination response; L. casei 431

한글 키워드

면역 기능; 프로바이오틱스; 상기도 감염; 락토바실러스 파라카제이; 예방접종 반응; 락토바실러스 파라카제이 431

KMCRIC summary and commentary

없음

Korean Study

Abstract

BACKGROUND:
Probiotics can modulate the immune system in healthy individuals and may help reduce symptoms related to respiratory infections.

OBJECTIVE:
The objective of the study was to investigate the effect of the probiotic strain Lactobacillus paracasei subsp. paracasei, L. casei 431 (Chr. Hansen A/S) (hereafter, L. casei 431) on immune response to influenza vaccination and respiratory symptoms in healthy adults.

DESIGN:
A randomized double-blind, placebo-controlled trial was conducted in 1104 healthy subjects aged 18-60 y at 2 centers in Germany and Denmark. Subjects were randomly assigned to receive an acidified milk drink containing ≥10(9) colony-forming units of L. casei 431 (n = 553) or placebo (n = 551) for 42 d. After 21 d, subjects received the seasonal influenza vaccination. The primary outcome was seroprotection rate (anti-influenza antibody titers by hemagglutination inhibition) 21 d after vaccination. Other outcomes were seroconversion rate and mean titers, influenza A-specific antibodies and incidence, and duration and severity of upper respiratory symptoms. Antibiotic use and use of health care resources were recorded.

RESULTS:
There was no effect of L. casei 431 on immune responses to influenza vaccination. Generalized linear mixed modeling showed a shorter duration of upper respiratory symptoms in the probiotic group than in the placebo group (mean ± SD: 6.4 ± 6.1 vs. 7.3 ± 9.7 d, P = 0.0059) in the last 3 wk of the intervention period. No statistically significant differences were found for incidence or severity.

CONCLUSIONS:
Daily consumption of L. casei 431 resulted in no observable effect on the components of the immune response to influenza vaccination but reduced the duration of upper respiratory symptoms. The trial was registered at www.isrctn.com as ISRCTN08280229.

국문초록

Language

영어

첨부파일